Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Anticancer Res. 2010 Oct;30(10):4223-7.
To evaluate whether expression of L-type amino acid transporter 1 (LAT1) in pretreatment rectal cancer biopsies is predictive of tumour response to neoadjuvant hyperthermo-chemoradiotherapy (HCRT).
Forty-four patients with rectal adenocarcinoma who received neoadjuvant HCRT were investigated. LAT1 expression was immunohistochemically evaluated using pretreatment biopsies. The operation was performed after 2-3 months following HCRT and each resected specimen was graded by the histological criteria of the Japanese Classification of Colorectal Carcinoma.
A positive LAT1 expression was recognized in 50.0% (22/44) of patients. Resected specimens were divided into 2 groups according to the histological grading criteria: good response (n=29) and poor response (n=15). LAT1-negative tumours had an 81.8% probability of good response and 18.2% probability of poor response. LAT1 expression showed marginally significant association with response to HCRT (p=0.05).
LAT1 may be a useful predictive marker of response to HCRT in rectal cancer.
评估预处理直肠癌活检中 L 型氨基酸转运蛋白 1（LAT1）的表达是否可预测肿瘤对新辅助热化疗（HCRT）的反应。
研究了 44 例接受新辅助 HCRT 的直肠腺癌患者。使用预处理活检通过免疫组织化学评估 LAT1 表达。HCRT 后 2-3 个月进行手术，根据日本大肠癌分类的组织学标准对每个切除标本进行分级。
50.0%（22/44）的患者中存在阳性 LAT1 表达。根据组织学分级标准，将切除标本分为 2 组：良好反应（n=29）和不良反应（n=15）。LAT1 阴性肿瘤具有 81.8%的良好反应概率和 18.2%的不良反应概率。LAT1 表达与 HCRT 反应呈显著相关（p=0.05）。
LAT1 可能是直肠癌对 HCRT 反应的有用预测标志物。
Zotero 插件